To expand on the science behind BeOne Medicine’s BTK Degrader, XVIVO developed a second medical animation, this time focusing on the broader CDAC platform.
CDACs, or chimeric degradation activating compounds, represent a promising new approach in cancer treatment. Unlike traditional inhibitors, these molecules selectively tag disease-driving proteins for degradation through the ubiquitin-proteasome pathway. The animation breaks down this process step by step, showing how CDACs are designed to bind and recruit enzymes that catalytically mark proteins for removal, to eliminate the need for continuous binding and inhibition.
This piece helps explain how BeOne’s platform could address treatment resistance and reach hard-to-target proteins across multiple disease areas. Together with the BTK degrader animation and interactive experience, it forms a cohesive set of tools to help BeOne’s scientific message connect with their audience.
If you’re looking to develop content that represents your scientific platform or clinical pipeline, please reach out to us! https://xvivo.com/contact-us/
Related Animations
